A novel Ras inhibitor (MDC-1016) reduces human pancreatic tumor growth in mice

Neoplasia (United States)

Volumn 15, Issue 10, 2013, Pages 1184-1195

  Mackenzie, Gerardo G ^a   Bartels, Lauren E ^a   Xie, Gang ^a   Papayannis, Ioannis ^a   Alston, Ninche ^a   Vrankova, Kvetoslava ^a   Ouyang, Nengtai ^a,b   Rigas, Basil ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b Medicon Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GLUCURONIDE; KI 67 ANTIGEN; MDC 1016; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHO FARNESYLTHIOSALICYLIC ACID; PHOSPHO VALPROIC ACID; PROTEIN INHIBITOR; PROTEIN KINASE B; RAS PROTEIN; SALIRASIB; UNCLASSIFIED DRUG; VALPROIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; FEMALE; GENE MUTATION; GENE REPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MOUSE; NICK END LABELING; NONHUMAN; ONCOGENE K RAS; PANCREAS ADENOMA; PANCREAS TUMOR; PANCREATITIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TANDEM MASS SPECTROMETRY; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOATES; CELL LINE, TUMOR; DRUG SYNERGISM; FEMALE; HETEROGRAFTS; HUMANS; METAPLASIA; MICE, INBRED BALB C; MICE, NUDE; ORGANOPHOSPHATES; PANCREATIC NEOPLASMS; PANCREATITIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; VALPROIC ACID;

EID: 84887029745     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.131368     Document Type: Article

References (36)

1. Hidalgo M (2010). Pancreatic cancer. N Engl J Med 362, 1605-1617.
2. Siegel R, Naishadham D, and Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin 62, 10-29.
3. Ying JE, Zhu LM, and Liu BX (2012). Developments in metastatic pancreatic cancer: is gemcitabine still the standard? World J Gastroenterol 18, 736-745.
4. Hruban RH, van Mansfeld AD, Offerhaus GJ, van Weering DH, Allison DC, Goodman SN, Kensler TW, Bose KK, Cameron JL, and Bos JL (1993). K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 143, 545-554.
5. Morris JP IV, Wang SC, and Hebrok M (2010). KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer 10, 683-695.
6. G12D activation of ERK2 specifically regulates 3D invasion of human pancreatic cancer cells via MMP-1. Mol Cancer Res 10, 183-196.
7. Collisson EA, Trejo CL, Silva JM, Gu S, Korkola JE, Heiser LM, Charles RP, Rabinovich BA, Hann B, Dankort D, et al. (2012). A central role for RAF→ MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov 2, 685-693.
8. Kip1. Cancer Res 65, 4870-4880.
9. Milella M, Kornblau SM, Estrov Z, Carter BZ, Lapillonne H, Harris D, Konopleva M, Zhao S, Estey E, and Andreeff M (2001). Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 108, 851-859.
10. Wilhelm S and Chien DS (2002). BAY 43-9006: preclinical data. Curr Pharma Des 8, 2255-2257.
11. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA, and McCubrey JA (2003). Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17, 590-603.
12. Luo HR, Hattori H, Hossain MA, Hester L, Huang Y, Lee-Kwon W, Donowitz M, Nagata E, and Snyder SH (2003). Akt as a mediator of cell death. Proc Natl Acad Sci USA 100, 11712-11717.
13. Parsons CM, Muilenburg D, Bowles TL, Virudachalam S, and Bold RJ (2010). The role of Akt activation in the response to chemotherapy in pancreatic cancer. Anticancer Res 30, 3279-3289.
14. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, and McConkey DJ (2002). Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 1, 989-997.
15. di Magliano MP and Logsdon CD (2013). Roles for KRAS in pancreatic tumor development and progression. Gastroenterology 144, 1220-1229.
16. Collins MA, Bednar F, Zhang Y, Brisset JC, Galban S, Galban CJ, Rakshit S, Flannagan KS, Adsay NV, and Pasca di Magliano M (2012). Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest 122, 639-653.
17. Laheru D, Shah P, Rajeshkumar NV, McAllister F, Taylor G, Goldsweig H, Le DT, Donehower R, Jimeno A, Linden S, et al. (2012). Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer. Invest New Drugs 30, 2391-2399.
18. Rotblat B, Ehrlich M, Haklai R, and Kloog Y (2008). The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer. Methods Enzymol 439, 467-489.
19. Goldberg L, Haklai R, Bauer V, Heiss A, and Kloog Y (2009). New derivatives of farnesylthiosalicylic acid (Salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models. J Med Chem 52, 197-205.
20. Huang L, Mackenzie G, Ouyang N, Sun Y, Xie G, Johnson F, Komninou D, and Rigas B (2011). The novel phospho-non-steroidal anti-inflammatory drugs, OXT-328, MDC-22 and MDC-917, inhibit adjuvant-induced arthritis in rats. Br J Pharmacol 162, 1521-1533.
21. Huang L, Mackenzie GG, Sun Y, Ouyang N, Xie G, Vrankova K, Komninou D, and Rigas B (2011). Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds. Cancer Res 71, 7617-7627.
22. Mackenzie GG, Sun Y, Huang L, Xie G, Ouyang N, Gupta RC, Johnson F, Komninou D, Kopelovich L, and Rigas B (2010). Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice. Gastroenterology 139, 1320-1332.
23. Mackenzie GG, Huang L, Alston N, Ouyang N, Vrankova K, Mattheolabakis G, Constantinides PP, and Rigas B (2013). Targeting mitochondrial STAT3 with the novel phospho-valproic acid (MDC-1112) inhibits pancreatic cancer growth in mice. PLoS One 8, e61532.
24. Mackenzie GG, Queisser N, Wolfson ML, Fraga CG, Adamo AM, and Oteiza PI (2008). Curcumin induces cell-arrest and apoptosis in association with the inhibition of constitutively active NF-κlB and STAT3 pathways in Hodgkin's lymphoma cells. Int J Cancer 123, 56-65.
25. Haklai R, Elad-Sfadia G, Egozi Y, and Kloog Y (2008). Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. Cancer Chemother Pharmacol 61, 89-96.
26. Mackenzie GG, Ouyang N, Xie G, Vrankova K, Huang L, Sun Y, Komninou D, Kopelovich L, and Rigas B (2011). Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice. Cancer Prev Res (Phila) 4, 1052-1060.
27. Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, Andersen JR, Dimagno EP, Andrén-Sandberg A, and Domellöf L (1993). International Pancreatitis Study Group Pancreatitis and the risk of pancreatic cancer. N Engl J Med 328, 1433-1437.
28. Guerra C, Schuhmacher AJ, Cañamero M, Grippo PJ, Verdaguer L, Pérez-Gallego L, Dubus P, Sandgren EP, and Barbacid M (2007). Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11, 291-302.
29. Fukuda A, Wang SC, Morris JP IV, Folias AE, Liou A, Kim GE, Akira S, Boucher KM, Firpo MA, Mulvihill SJ, et al. (2011). Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 19, 441-455.
30. Meyskens FL Jr, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, et al. (2008). Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) 1, 32-38.
31. Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Klöppel G, Yoshimura A, Reindl W, Sipos B, Akira S, et al. (2011). Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19, 456-469.
32. Sun Y, Huang L, Mackenzie GG, and Rigas B (2011). Oxidative stress mediates through apoptosis the anticancer effect of phospho-nonsteroidal anti-inflammatory drugs: implications for the role of oxidative stress in the action of anticancer agents. J Pharmacol Exp Ther 338, 775-783.
33. Sun Y, Rowehl LM, Huang L, Machenzie GG, Vrankova K, Komninou D, and Rigas B (2012). Phospho-ibuprofen (MDC-917) suppresses breast cancer growth: an effect controlled by the thioredoxin system. Breast Cancer Res 14, R20.
34. Mortenson MM, Galante JM, Schlieman MG, and Bold RJ (2004). AKT: a novel target in pancreatic cancer therapy. Cancer Ther 2, 227-238.
35. Chou TC (2006). Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58, 621-681.
36. Corcoran RB, Contino G, Deshpande V, Tzatsos A, Conrad C, Benes CH, Levy DE, Settleman J, Engelman JA, and Bardeesy N (2011). STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res 71, 5020-5029.